RG-HRV16 Inoculum Dose Determination

The study will have a single-blind, 5+5 design for dose finding with dose de-escalation with a maximum of 4 groups of up to 10 healthy, HRV16 seronegative adult subjects inoculated with either placebo or a dose of 100, 500, 1000 or 10,000 TCD50 of RG-HRV16. Household or close contacts of research subjects will be invited to join in a surveillance portion of the protocol in order to obtain safety information on the transmission and severity of RG-HRV16 colds.